IGF-1 LR3 and PEG-MGF Interaction
IGF-1 LR3 and PEG-MGF have an interaction requiring monitoring for interaction with 90% confidence. Both target IGF-1 pathways; combining risks receptor overstimulation. Reduce doses significantly if combined. Both compounds affect the blood vessels and pituitary, so monitoring these systems is recommended.
Compound Profiles
IGF-1 LR3
Modified Growth Factor Analog | Muscle Growth
Functions as a full IGF-1 receptor agonist activating PI3K/Akt/mTOR and MAPK/ERK pathways. The modifications prevent protein sequestration, maintaining elevated free circulating levels for extended anabolic effects.
View full profilePEG-MGF
Pegylated Mechano Growth Factor | IGF-1 Splice Variant
Activates muscle satellite stem cells via receptor binding, stimulating MAPK/ERK signaling. Enhances protein synthesis and promotes muscle fiber repair.
View full profileCombined Organ Load
Shared Safety Flags
Frequently Asked Questions
Can I take IGF-1 LR3 with PEG-MGF?
Yes, but with caution. Both target IGF-1 pathways; combining risks receptor overstimulation. Reduce doses significantly if combined. Regular monitoring is advised.
Is IGF-1 LR3 and PEG-MGF safe together?
Based on documented research, this combination is considered monitor. However, shared safety flags include: carcinogenic risk, insulin disrupting. Monitor accordingly.
What are the interactions between IGF-1 LR3 and PEG-MGF?
Both target IGF-1 pathways; combining risks receptor overstimulation. Reduce doses significantly if combined. This assessment has 90% confidence and is based on documented research data.
How should I time IGF-1 LR3 and PEG-MGF?
IGF-1 LR3 has a half-life of 20-30 hours and PEG-MGF has a half-life of 48-72 hours (via PEGylation). No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.
This interaction analysis is compiled from research literature and pharmacological mechanism data. Always consult a healthcare professional before combining compounds.